Cas:202480-70-4 eicosanoic-20,20,20-d3 acid manufacturer & supplier

Chemical Name:eicosanoic-20,20,20-d3 acid

CAS.NO:202480-70-4

Synonyms:eicosanoic-20,20,20-d3 acid

Molecular Formula:C₂₀H₃₇D₃O₂

Molecular Weight:315.54900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:37.30000

Exact Mass:315.32200

LogP:7.11270

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like eicosanoic-20,20,20-d3 acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,eicosanoic-20,20,20-d3 acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,eicosanoic-20,20,20-d3 acid Use and application,eicosanoic-20,20,20-d3 acid technical grade,usp/ep/jp grade.

Related News: At present, there are more than 8,000 domestic API manufacturers, but they mainly produce bulk APIs with low technical content. eicosanoic-20,20,20-d3 acid manufacturer Retrogenix holds two Queen��s Awards for Enterprise, the UK��s most prestigious acknowledgement of business performance. The company is headquartered near Manchester, UK, and has an office in Cambridge, MA. eicosanoic-20,20,20-d3 acid supplier The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. eicosanoic-20,20,20-d3 acid vendor The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. eicosanoic-20,20,20-d3 acid factory South Korea and Japan are barring noncitizens who traveled recently to Hubei, the province at the center of the outbreak.